Neuromodulation Devices Global Market- Forecast to 2029

Publishing Date : September, 2022
Report Code : HCMD0131
Price:
Single license $4,950
Site license $6,750
Global license $9,000


Note: The report would be dispatched after confirmation of payment

Neuromodulation treatment involves direct stimulation or modulation of the nerves by an electrical or magnetic field. It is used as a treatment for unmanageable chronic pain, movement disorders, neurological diseases, gastroenterology, respiratory related diseases and others. The treatment delivered by neuromodulation devices brings about life-changing transformation in patients who fail to get better by traditional approaches. This therapy is based on the natural process of stimulation of nerve cell activity and release of neurotransmitters that regulate nerve activity. Neuromodulation is gaining popularity because these devices have been very successful in the treatment of conditions for which medicines have failed completely or may have unpleasant side effects.

The neuromodulation global market is expected to grow at a high single digit CAGR from 2022 to 2029 to reach $9,569.4 million by 2029 due to increasing incidence of chronic pain, increasing parkinson’s and alzheimer’s disorders, low approval rate of CNS drugs, favorable reimbursement scenario in major markets, the emergence of neuromodulation as add-on therapy, technological innovations, rise in the number of clinical studies performed and expansion in emerging markets. The neuromodulation devices market is segmented into product, application, end-user, and geography.

Based on the product, the neuromodulation global market is segmented into invasive neuromodulation devices and non-invasive neuromodulation devices. Among these, invasive neuromodulation devices segment accounted for the highest revenue in 2022 and is expected to grow at an early teen CAGR from 2022 to 2029. Invasive neuromodulation devices market is segmented into Spinal Cord Stimulator (SCS), Deep Brain Stimulator (DBS), Sacral Nerve Stimulator (SNS), Vagus Nerve Stimulator (VNS), Hypoglossal Nerve Stimulator (HGNS) and others include Gastric Electric Stimulation (GES), Respiratory Electrical Stimulation (RES) or Phrenic Nerve Stimulation (PNS). Among invasive neuromodulation devices, Spinal cord stimulator (SCS) segment accounted for the largest revenue in 2022 and is expected to grow at a mid-single digit CAGR from 2022 to 2029 due to increase in the incidence of chronic pain, increase in movement disorders and high implantation rate of spinal cord stimulators. The Hypoglossal Nerve Stimulator segment is expected to grow at a high double digit CAGR from 2022 to 2029. The non-invasive neuromodulation devices market is segmented into Transcutaneous Electrical Nerve Stimulation (TENS), Neuromuscular Electrical Stimulation (NMES) and others. Among these, Transcutaneous Electrical Nerve Stimulator (TENS) segment is the largest and fastest growing segment accounted for the highest revenue in 2022 and is expected to grow at mid-single digit CAGR from 2022 to 2029.

Based on the application, the neuromodulation devices global market is segmented into Pain Management, Central Nervous System, Gastroenterology and Urology, Obstructive Sleep Apnea (OSA) and other applications include Obesity, Heart Failure, Autoimmune diseases (rheumatoid arthritis), respiratory related diseases (diaphragm pacing), Diabetes and Weaning. Among these, pain management segment accounted for the largest revenue in 2022 and is expected to grow at mid-single digit CAGR from 2022 to 2029. Obstructive Sleep Apnea segment is expected to grow at a high double digit CAGR from 2022 to 2029.

Pain management is further segmented into chronic pain, failed back surgery syndrome (FBSS) and others. Among these, chronic pain segment accounted for the largest revenue in 2022 and is expected to grow at mid-single digit CAGR from 2022 to 2029 due to increasing incidence of chronic pain, increasing utilizing of the spinal cord stimulators and advancement in neuromodulation devices.

Central Nervous System is further segmented into Parkinson’s disease, Dystonia, Epilepsy and others include Obsessive Compulsive Disorder (OCD), Depression, Stroke, and Mood disorders, Anxiety, Central Sleep Apnea and Multiple Sclerosis. Among these, Parkinson’s disease segment accounted for the largest revenue in 2022 and is expected to grow at mid-single digit CAGR from 2022 to 2029. Epilepsy segment is expected to grow at a high double digit CAGR from 2022 to 2029.

Gastroenterology and Urology is further segmented into Gastroparesis, Urinary Incontinence and Faecal Incontinence. Among these, Urinary Incontinence segment accounted for the largest revenue in 2022 and is expected to grow at a mid-single digit CAGR from 2022 to 2029.

Based on the end-user, the neuromodulation devices global market is segmented into Hospitals and Ambulatory Surgery Centers, Clinics and Physiotherapy Centers and Others include Home care, Academics and Research Institutes. Among these, Hospitals and Ambulatory Surgery Centers is the largest revenue in 2022 and is expected to grow at a high single digit CAGR from 2022 to 2029.

Based on the region, the neuromodulation devices global market is segmented into North America (U.S. and Rest of North America), Europe (Germany, France, U.K and Rest of Europe), Asia-Pacific (Japan, China, India, and Rest of APAC) and Rest of the world (Brazil, Rest of Latin America and Middle East & others). North America accounted for the largest revenue in 2022 and is expected to grow at a high single digit CAGR from 2022 to 2029 due to high technological advancements, increased growing awareness about medical care, treatment style, increase in the aging population, strong product pipeline, new indications, investments and funds, increases in neurological diseases, sophisticated infrastructure related to healthcare and high expenditure present among the population of North America are boosting the market of neuromodulation devices. Asia-Pacific is the fastest growing segment accounted for the highest revenue in 2022 and is expected to grow at a high double digit CAGR from 2022 to 2029 due to rising incidences of neurological disorders, government initiatives to increasing awareness by education campaigns, large pool of patients, increasing geriatric population, advancements in surgeries and technologies, increased healthcare facilities, increasing adoption of implantable devices, high acceptance of technological advancements, the easy availability of advanced healthcare technology, skilled personnel and low-cost for the surgery are driving the market.

The neuromodulation devices global market is a highly consolidated market hence all the existing players in this market are involved in developing new and advanced technologies to maintain their market shares. Some of the major players in Neuromodulation devices market include Abbott Laboratories (U.S.), Axonics Inc. (U.S.), Bioventus (Bioness Inc.) (U.S.), Boston Scientific Corporation (U.S.), Inspire Medical System Inc. (U.S.), Laborie Medical (Canada), LivaNova Plc (U.K.), Medtronic Plc (Ireland), NeuroPace Inc. (U.S.) and Nevro Corporation (U.S.).

The report provides an in-depth market analysis of the above-mentioned segments across the following regions:

  • North America
  • U.S.
  • Rest of North America
  • Europe
  • Germany
  • France
  • U.K.
  • Rest of Europe
  • Asia-Pacific 
  • Japan
  • China
  • India
  • Rest of APAC
  • Rest of the World (RoW)
  • Brazil
  • Rest of Latin America
  • Middle East and Others

 

  • 1     EXECUTIVE SUMMARY
  • 2     INTRODUCTION
    • 2.1     KEY TAKEAWAYS
    • 2.2     SCOPE OF THE REPORT
    • 2.3     REPORT DESCRIPTION
    • 2.4     MARKETS COVERED
    • 2.5     STAKEHOLDERS
    • 2.6     RESEARCH METHODOLOGY
      • 2.6.1     MARKET SIZE ESTIMATION
      • 2.6.2     MARKET BREAKDOWN AND DATA TRIANGULATION
      • 2.6.3     SECONDARY SOURCES
      • 2.6.4     PRIMARY SOURCES
      • 2.6.5     KEY DATA POINTS FROM SECONDARY SOURCES
      • 2.6.6     KEY DATA POINTS FROM PRIMARY SOURCES
      • 2.6.7     ASSUMPTIONS
  • 3     MARKET ANALYSIS
    • 3.1     INTRODUCTION
    • 3.2     MARKET SEGMENTATION
    • 3.3     FACTORS INFLUENCING MARKET
      • 3.3.1     DRIVERS AND OPPORTUNITIES
        • 3.3.1.1.     GROWING PREVALENCE OF TREATMENT RESISTANT CHRONIC CONDITIONS TO FUEL THE DEMAND FOR NEUROMODULATION DEVICES
        • 3.3.1.2.     GROWING PREVALENCE OF PARKINSON'S, ALZHEIMER'S DISEASES, NEUROLOGICAL AND RESPIRATORY CONDITIONS TO DRIVE THE MARKET
        • 3.3.1.3.     LOW APPROVAL RATE OF CNS DRUGS IS DRIVING NEUROMODULATION MARKET
        • 3.3.1.4.     FAVORABLE REIMBURSEMENT SCENARIO IN MAJOR MARKETS
        • 3.3.1.5.     THE EMERGENCE OF NEUROMODULATION AS ADD-ON THERAPY
        • 3.3.1.6.     TECHNOLOGICAL AINNOVATIONS IN NEUROMODULATION
        • 3.3.1.7.     EXPANSION IN EMERGING MARKETS
        • 3.3.1.8.     THE RISE IN THE NUMBER OF CLINICAL STUDIES PERFORMED
    • 3.3.2     RESTRAINTS AND THREATS
      • 3.3.2.1     SIDE EFFECTS AND RISK ASSOCIATED WITH THE USE
      • 3.3.2.2     LACK OF TRAINED PROFESSIONALS
      • 3.3.2.3     AVAILABILITY OF ALTERNATIVE TREATMENTS
      • 3.3.2.4      STRINGENT REGULATORY GUIDELINES
  • 3.4     REGULATORY AFFAIRS
    • 3.4.1     INTERNATIONAL ORGANIZATION FOR STANDARDIZATION
      • 3.4.1.1     ISO 9001: 2015 Quality Management system
      • 3.4.1.2     ISO 13485 Medical devices
      • 3.4.1.3     ISO 10993 Biological evaluation of medical devices
    • 3.4.2     U.S.
    • 3.4.3     CANADA
    • 3.4.4     EUROPE
    • 3.4.5     JAPAN
    • 3.4.6     CHINA
    • 3.4.7     INDIA
  • 3.5     CLINICAL TRIALS DATA
  • 3.6     TECHNOLOGICAL ADVANCEMENTS
    • 3.6.1     RECHARGEABLE SYSTEMS
    • 3.6.2     OPTOGENETIC TECHNOLOGY
    • 3.6.3     FOCUSED ULTRASOUND (FUS)
    • 3.6.4     MINIATURIZATION
    • 3.6.5     PORTABLE NUEROMODULATION SYSTEMS (PONS)
    • 3.6.6     WEARABLE PAIN MANAGEMENT TECHNOLOGY
    • 3.6.7     TRANS-SPINAL DIRECT CURRENT STIMULATION (TSDCS)
    • 3.6.8     NANO-NEUROMODULATION
    • 3.6.9     BIOACTIVE COATINGS
    • 3.6.10     OCCIPITAL NERVE STIMULATION (ONS)
    • 3.6.11     CRANIAL ELECTROTHERAPY STIMULATION (CES)
  • 3.7     PORTER’S FIVE FORCE ANALYSIS
    • 3.7.1     THREAT OF NEW ENTRANTS
    • 3.7.2     THREAT OF SUBSTITUTES
    • 3.7.3     BARGAINING POWER OF SUPPLIERS
    • 3.7.4     BARGAINING POWER OF BUYERS
    • 3.7.5     COMPETITIVE RIVALRY
  • 3.8     SUPPLY CHAIN ANALYSIS
  • 3.9     IMPACT OF COVID-19 ON NEUROMODULATION DEVICES
  • 3.1     REIMBURSEMENT SCENARIO
    • 3.10.1     REIMBURSEMENT TABLE
  • 3.11     REGULATORY APPROVED NEUROMODULATION DEVICES
    • 3.11.1     SPINAL CORD STIMULATORS (SCS)
    • 3.11.2     TRANSCUTANEOUS ELECTRICAL NERVE STIMULATOR (TENS)
    • 3.11.3     DEEP BRAIN STIMULATION (DBS)
    • 3.11.4     SACRAL NERVE STIMULATION (SNS)
    • 3.11.5     VAGUS NERVE STIMULATION (VNS)
    • 3.11.6     TRANSCRANIAL MAGNETIC STIMULATION (TMS)
  • 3.12     FUNDING SCENARIO
  • 3.13     MARKET SHARE ANALYSIS BY MAJOR PLAYERS
    • 3.13.1     NEUROMODULATION DEVICES GLOBAL MARKET SHARE ANALYSIS
    • 3.13.2     SPINAL CORD STIMULATORS GLOBAL MARKET SHARE ANALYSIS
    • 3.13.3     DEEP BRAIN STIMULATORS GLOBAL MARKET SHARE ANALYSIS
    • 3.13.4     SACRAL NERVE STIMULATOR (SNS) GLOBAL MARKET SHARE ANALYSIS
    • 3.13.5     HYPOGLOSSAL NERVE STIMULATOR (HGNS) GLOBAL MARKET SHARE ANALYSIS
  • 3.14     NEUROMODULATION DEVICES NUMBER OF UNITS BASED ON REGION
    • 3.14.1     SPINAL CORD STIMULATION (SCS) NUMBER OF UNITS BASED ON REGION
    • 3.14.2     DEEP BRAIN STIMULATION (DBS) NUMBER OF UNITS BASED ON REGION
    • 3.14.3     SACRAL NERVE STIMULATION (SNS) NUMBER OF UNITS
    • 3.14.4     VAGUS NERVE STIMULATION (VNS) NUMBER OF UNITS BEASED ON REGION
    • 3.14.5     HYPOGLOSSAL NERVE STIMULATION (HGNS) NUMBER OF UNITS BASED ON REGION
  • 3.15     MARKET PENETRATION
    • 3.15.1     UNITED STATES OBSTRUCTIVE SLEEP APNEA NEUROMODULATION DEVICES MARKET PENETRATION ANALYSIS
    • 3.15.2     UNITED STATES DRUG RESISTANT EPILEPSY NEUROMODULATION DEVICES MARKET PENETRATION ANALYSIS
    • 3.15.3     UNITED STATES DEPRESSION NEUROMODULATION DEVICES MARKET PENETRATION ANALYSIS
    • 3.15.4     UNITED STATES OVERACTIVE BLADDER NEUROMODULATION DEVICES MARKET PENETRATION ANALYSIS
    • 3.15.5     UNITED STATES CHRONIC PAIN NEUROMODULATION DEVICES MARKET PENETRATION ANALYSIS
  • 3.16     NEUROMODULATION DEVICES COMPANY COMPARISON TABLE BY REVENUE, TECHNOLOGY, PRODUCTS AND APPLICATION
  • 4     NEUROMODULATION DEVICES GLOBAL MARKET, BASED ON PRODUCT
    • 4.1     INTRODUCTION
    • 4.2     INVASIVE NEUROMODULATION DEVICES
      • 4.2.1     SPINAL CORD STIMULATION (SCS)
      • 4.2.2     DEEP BRAIN STIMULATION (DBS)
      • 4.2.3     SACRAL NERVE STIMULATION (SNS)
      • 4.2.4     VAGUS NERVE STIMULATION (VNS)
      • 4.2.5     HYPOGLOSSAL NERVE STIMULATION (HGNS)
      • 4.2.6     OTHER INVASIVE NEUROMODULATION DEVICES
        • 4.2.6.1     GASTRIC ELECTRIC STIMULATION (GES)
        • 4.2.6.2     RESPIRATORY ELECTRICAL STIMULATION (RES)/PHRENIC NERVE STIMULATION (PNS)
    • 4.3     NON-INVASIVE NEUROMODULATION DEVICES
      • 4.3.1     TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION (TENS)
      • 4.3.2     NEUROMUSCULAR ELECTRICAL STIMULATION (NMES)
      • 4.3.3     OTHER NON-INVASIVE NEUROMODULATION DEVICES
        • 4.3.3.1     TRANSCRANIAL MAGNETIC STIMULATION (TMS)
        • 4.3.3.2     FUNCTIONAL ELECTRICAL STIMULATION (FES)
        • 4.3.3.3     ELECTROCONVULSIVE THERAPY (ECT)
        • 4.3.3.4     PERCUTANEOUS TIBIAL NERVE STIMULATION (PTNS)
        • 4.3.3.5     PORTABLE NEUROMODULATION STIMULATION (PONS)
        • 4.3.3.6     TRANSCRANIAL ELECTRICAL STIMULATION (TES)
        • 4.3.3.7     TRANSCRANIAL DIRECT CURRENT STIMULATION (TDCS)
        • 4.3.3.8     TRANSCRANIAL ALTERNATING CURRENT STIMULATION (TACS)
        • 4.3.3.9     PERIPHERAL NERVE STIMULATION (PNS)
        • 4.3.3.10     TRIGEMINAL NERVE STIMULATION (TNS)
        • 4.3.3.11     COORDINATED RESET NEUROMODULATION (CR NEUROMODULATION)
        • 4.3.3.12     PERCUTANEOUS ELECTRICAL NERVE STIMULATION (PENS)
        • 4.3.3.13     TRANSCRANIAL ELECTROMAGNETIC TREATMENT (TEMT)
        • 4.3.3.14     PERCUTANEOUS ELECTRIC NERVE FIELD STIMULATION (PENFS)
        • 4.3.3.15     TRANSCUTANEOUS SUPRAORBITAL NEUROSTIMULATION (TSNS)
        • 4.3.3.16     OCCIPITAL NERVE STIMULATION (ONS)
        • 4.3.3.17     CRANIAL ELECTROTHERAPY STIMULATION (CES)
  • 5     NEUROMODULATION DEVICES GLOBAL MARKET, BASED ON APPLICATION
    • 5.1     INTRODUCTION
    • 5.2     PAIN MANAGEMENT
      • 5.2.1     CHRONIC PAIN
      • 5.2.2     FAILED BACK SURGERY SYNDROME (FBSS)
      • 5.2.3     OTHER PAIN MANAGEMENT
    • 5.3     CENTRAL NERVOUS SYSTEM (CNS)
      • 5.3.1     PARKINSON'S DISEASE
      • 5.3.2     DYSTONIA
      • 5.3.3     EPILEPSY
      • 5.3.4     OTHERS
    • 5.4     GASTROENTEROLOGY AND UROLOGY
      • 5.4.1     GASTROPARESIS
      • 5.4.2     URINARY INCONTINENCE
      • 5.4.3     FAECAL INCONTINENCE
    • 5.5     OBSTRUCTIVE SLEEP APNEA (OSA)
    • 5.6     OTHER APPLICATIONS
  • 6     NEUROMODULATION DEVICES GLOBAL MARKET, BASED ON END-USERS
    • 6.1     INTRODUCTION
    • 6.2     HOSPITALS AND AMBULATORY SURGERY CENTERS (ASC)
    • 6.3     CLINICS AND PHYSIOTHERAPY CENTERS
    • 6.4     OTHERS (HOME CARE, ACADEMICS AND RESEARCH INSTITUTES)
  • 7     REGIONAL ANALYSIS
    • 7.1     INTRODUCTION
    • 7.2     NORTH AMERICA
      • 7.2.1     UNITED STATES (U.S.)
      • 7.2.2     REST OF NORTH AMERICA
    • 7.3     EUROPE
      • 7.3.1     GERMANY
      • 7.3.2     FRANCE
      • 7.3.3     UNITED KINGDOM (U.K.)
      • 7.3.4     REST OF EUROPE
    • 7.4     APAC
      • 7.4.1     JAPAN
      • 7.4.2     CHINA
      • 7.4.3     INDIA
      • 7.4.4     REST OF APAC
    • 7.5     REST OF THE WORLD (ROW)
      • 7.5.1     BRAZIL
      • 7.5.2     REST OF LATIN AMERICA (LATAM)
      • 7.5.3     MIDDLE EAST AND OTHERS
  • 8     COMPETITIVE LANDSCAPE
    • 8.1     INTRODUCTION
    • 8.2     PRODUCT APPROVAL
    • 8.3     PRODUCT LAUNCH
    • 8.4     EXPANSION AND ACQUISITION
    • 8.5     AGREEMENT AND COLLABORATION
    • 8.6     OTHER DEVELOPMENTS
  • 9     MAJOR COMPANIES
    • 9.1     ABBOTT LABORATORIES
      • 9.1.1     OVERVIEW
      • 9.1.2     FINANCIALS
      • 9.1.3     PRODUCT PORTFOLIO
      • 9.1.4     KEY DEVELOPMENTS
      • 9.1.5     BUSINESS STRATEGY
      • 9.1.6     SWOT ANALYSIS
    • 9.2     AXONICS INC.
      • 9.2.1     OVERVIEW
      • 9.2.2     FINANCIALS
      • 9.2.3     PRODUCT PORTFOLIO
      • 9.2.4     KEY DEVELOPMENTS
      • 9.2.5     BUSINESS STRATEGY
      • 9.2.6     SWOT ANALYSIS
    • 9.3     BIOVENTUS (BIONESS INC)
      • 9.3.1     OVERVIEW
      • 9.3.2     FINANCIALS
      • 9.3.3     PRODUCT PORTFOLIO
      • 9.3.4     KEY DEVELOPMENTS
      • 9.3.5     BUSINESS STRATEGY
      • 9.3.6     SWOT ANALYSIS
    • 9.4     BOSTON SCIENTIFIC CORPOARTION
      • 9.4.1     OVERVIEW
      • 9.4.2     FINANCIALS
      • 9.4.3     PRODUCT PORTFOLIO
      • 9.4.4     KEY DEVELOPMENTS
      • 9.4.5     BUSINESS STRATEGY
      • 9.4.6     SWOT ANALYSIS
    • 9.5     INSPIRE MEDICAL SYSTEM, INC.
      • 9.5.1     OVERVIEW
      • 9.5.2     FINANCIALS
      • 9.5.3     PRODUCT PORTFOLIO
      • 9.5.4     KEY DEVELOPMENTS
      • 9.5.5     BUSINESS STRATEGY
      • 9.5.6     SWOT ANALYSIS
    • 9.6     LABORIE MEDICAL TECHNOLOGIES, INC. (COGENTIX MEDICAL)
      • 9.6.1     OVERVIEW
      • 9.6.2     FINANCIALS
      • 9.6.3     PRODUCT PORTFOLIO
      • 9.6.4     KEY DEVELOPMENTS
      • 9.6.5     BUSINESS STRATEGY
      • 9.6.6     SWOT ANALYSIS
    • 9.7     LIVANOVA PLC (SORIN GROUP)
      • 9.7.1     OVERVIEW
      • 9.7.2     FINANCIALS
      • 9.7.3     PRODUCT PORTFOLIO
      • 9.7.4     KEY DEVELOPMENTS
      • 9.7.5     BUSINESS STRATEGY
      • 9.7.6     SWOT ANALYSIS
    • 9.8     MEDTRONIC PLC
      • 9.8.1     OVERVIEW
      • 9.8.2     FINANCIALS
      • 9.8.3     PRODUCT PORTFOLIO
      • 9.8.4     KEY DEVELOPMENTS
      • 9.8.5     BUSINESS STRATEGY
      • 9.8.6     SWOT ANALYSIS
    • 9.9     NEUROPACE, INC.
      • 9.9.1     OVERVIEW
      • 9.9.2     FINANCIALS
      • 9.9.3     PRODUCT PORTFOLIO
      • 9.9.4     KEY DEVELOPMENTS
      • 9.9.5     BUSINESS STRATEGY
      • 9.9.6     SWOT ANALYSIS
    • 9.1     NEVRO CORPOARTION
      • 9.10.1     OVERVIEW
      • 9.10.2     FINANCIALS
      • 9.10.3     PRODUCT PORTFOLIO
      • 9.10.4     KEY DEVELOPMENTS
      • 9.10.5     BUSINESS STRATEGY
      • 9.10.6     SWOT ANALYSIS

      LIST OF TABLES

      • TABLE 1     NEUROMODULATION DEVICES GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
      • TABLE 2     SCS NUMBER OF UNITS, BASED ON REGION, (2021-2029) (NO’S)
      • TABLE 3     DBS NUMBER OF UNITS, BASED ON REGION, (2021-2029) (NO’S)
      • TABLE 4     SNS NUMBER OF UNITS, BASED ON REGION, (2021-2029) (NO’S)
      • TABLE 5     VNS NUMBER OF UNITS, BASED ON REGION, (2021-2029) (NO’S)
      • TABLE 6     VNS NUMBER OF UNITS, BASED ON REGION, (2021-2029) (NO’S)
      • TABLE 7     NEUROMODULATION DEVICES GLOBAL MARKET REVENUE, BASED ON PRODUCT, (2021-2029) ($MN)
      • TABLE 8     NEUROMODULATION DEVICES GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
      • TABLE 9     INVASIVE NEUROMODULATION DEVICES GLOBAL MARKET REVENUE, BASED ON PRODUCT TYPE, (2021-2029) ($MN)
      • TABLE 10     INVASIVE NEUROMODULATION DEVICES GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
      • TABLE 11     SPINAL CORD STIMULATION (SCS) GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
      • TABLE 12     DEEP BRAIN STIMULATION (DBS) GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
      • TABLE 13     SACRAL NERVE STIMULATION (SNS) GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
      • TABLE 14     VAGUS NERVE STIMULATION (VNS) GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
      • TABLE 15     HYPOGLOSSAL NERVE STIMULATION (HGNS) GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
      • TABLE 16     OTHER INVASIVE NEUROMODULATION DEVICES GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
      • TABLE 17     NON-INVASIVE NEUROMODULATION DEVICES GLOBAL MARKET REVENUE, BASED ON PRODUCT TYPE, (2021-2029) ($MN)
      • TABLE 18     NON-INVASIVE NEUROMODULATION DEVICES GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
      • TABLE 19     TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION (TENS) GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
      • TABLE 20     NEUROMUSCULAR ELECTRICAL STIMULATION (NMES) GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
      • TABLE 21     OTHER NON-INVASIVE NEUROMODULATION DEVICES GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
      • TABLE 22     NEUROMODULATION DEVICES GLOBAL MARKET REVENUE, BASED ON APPLICATION, (2021-2029) ($MN)
      • TABLE 23     PAIN MANAGEMENT GLOBAL MARKET REVENUE, BASED ON APPLICATION TYPE, (2021-2029) ($MN)
      • TABLE 24     PAIN MANAGEMENT GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
      • TABLE 25     CHRONIC PAIN GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
      • TABLE 26     FAILED BACK SURGERY SYNDROME (FBSS) GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
      • TABLE 27     OTHER PAIN MANAGEMENT GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
      • TABLE 28     CENTRAL NERVOUS SYSTEM (CNS) GLOBAL MARKET REVENUE, BASED ON APPLICATION TYPE, (2021-2029) ($MN)
      • TABLE 29     CENTRAL NERVOUS SYSTEM (CNS) GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
      • TABLE 30     PARKINSON'S DISEASE GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
      • TABLE 31     DYSTONIA GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
      • TABLE 32     EPILEPSY GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
      • TABLE 33     OTHERS GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
      • TABLE 34     GASTROENTEROLOGY AND UROLOGY GLOBAL MARKET REVENUE, BASED ON APPLICATION TYPE, (2021-2029) ($MN)
      • TABLE 35     GASTROENTEROLOGY AND UROLOGY GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
      • TABLE 36     GASTROPARESIS GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
      • TABLE 37     URINARY INCONTINENCE GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
      • TABLE 38     FAECAL INCONTINENCE GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
      • TABLE 39     OBSTRUCTIVE SLEEP APNEA GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
      • TABLE 40     OTHER APPLICATIONS GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
      • TABLE 41     NEUROMODULATION DEVICES GLOBAL MARKET REVENUE, BASED ON END-USERS, (2021-2029) ($MN)
      • TABLE 42     HOSPITALS AND AMBULATORY SURGERY CENTERS (ASC) GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
      • TABLE 43     CLINICS AND PHYSIOTHERAPY CENTERS GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
      • TABLE 44     OTHERS GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
      • TABLE 45     NEUROMODULATION DEVICES GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
      • TABLE 46     NORTH AMERICA NEUROMODULATION DEVICES MARKET REVENUE, BASED ON PRODUCT, (2021-2029) ($MN)
      • TABLE 47     NORTH AMERICA INVASIVE NEUROMODULATION DEVICES MARKET REVENUE, BASED ON PRODUCT TYPE, (2021-2029) ($MN)
      • TABLE 48     NORTH AMERICA NON-INVASIVE NEUROMODULATION DEVICES MARKET REVENUE, BASED ON PRODUCT TYPE, (2021-2029) ($MN)
      • TABLE 49     NORTH AMERICA NEUROMODULATION DEVICES MARKET REVENUE, BASED ON APPLICATION, (2021-2029) ($MN)
      • TABLE 50     NORTH AMERICA PAIN MANAGEMENT MARKET REVENUE, BASED ON APPLICATION TYPE, (2021-2029) ($MN)
      • TABLE 51     NORTH AMERICA CENTRAL NERVOUS SYSTEM MARKET REVENUE, BASED ON APPLICATION TYPE, (2021-2029) ($MN)
      • TABLE 52     NORTH AMERICA GASTROENTEROLOGY AND UROLOGY MARKET REVENUE, BASED ON APPLICATION TYPE, (2021-2029) ($MN)
      • TABLE 53     NORTH AMERICA NEUROMODULATION DEVICES MARKET REVENUE, BASED ON END-USERS, (2021-2029) ($MN)
      • TABLE 54     NORTH AMERICA NEUROMODULATION DEVICES MARKET REVENUE, BASED ON COUNTRY, (2021-2029) ($MN)
      • TABLE 55     UNITED STATES NEUROMODULATION DEVICES GLOBAL MARKET REVENUE, BASED ON PRODUCTS (2022) ($ MN)
      • TABLE 56     REST OF NORTH AMERICA NEUROMODULATION DEVICES GLOBAL MARKET REVENUE, BASED ON PRODUCTS (2022) ($ MN)
      • TABLE 57     EUROPE NEUROMODULATION DEVICES MARKET REVENUE, BASED ON PRODUCT, (2021-2029) ($MN)
      • TABLE 58     EUROPE INVASIVE NEUROMODULATION DEVICES MARKET REVENUE, BASED ON PRODUCT TYPE, (2021-2029) ($MN)
      • TABLE 59     EUROPE NON-INVASIVE NEUROMODULATION DEVICES MARKET REVENUE, BASED ON PRODUCT TYPE, (2021-2029) ($MN)
      • TABLE 60     EUROPE NEUROMODULATION MARKET REVENUE, BASED ON APPLICATION, (2021-2029) ($MN)
      • TABLE 61     EUROPE PAIN MANAGEMENT MARKET REVENUE, BASED ON APPLICATION TYPE, (2021-2029) ($MN)
      • TABLE 62     EUROPE CENTRAL NERVOUS SYSTEM MARKET REVENUE, BASED ON APPLICATION TYPE, (2021-2029) ($MN)
      • TABLE 63     EUROPE GASTROENTEROLOGY AND UROLOGY MARKET REVENUE, BASED ON APPLICATION TYPE, (2021-2029) ($MN)
      • TABLE 64     EUROPE NEUROMODULATION DEVICES MARKET REVENUE, BASED ON END-USERS, (2021-2029) ($MN)
      • TABLE 65     EUROPE NEUROMODULATION DEVICES MARKET REVENUE, BASED ON COUNTRY, (2021-2029) ($MN)
      • TABLE 66     GERMANY NEUROMODULATION DEVICES GLOBAL MARKET REVENUE, BASED ON PRODUCTS (2022) ($ MN)
      • TABLE 67     FRANCE NEUROMODULATION DEVICES GLOBAL MARKET REVENUE, BASED ON PRODUCTS (2022) ($ MN)
      • TABLE 68     UNITED KINGDOM NEUROMODULATION DEVICES GLOBAL MARKET REVENUE, BASED ON PRODUCTS (2022) ($ MN)
      • TABLE 69     REST OF EUROPE NEUROMODULATION DEVICES GLOBAL MARKET REVENUE, BASED ON PRODUCTS (2022) ($ MN)
      • TABLE 70     APAC NEUROMODULATION DEVICES MARKET REVENUE, BASED ON PRODUCT, (2021-2029) ($MN)
      • TABLE 71     APAC INVASIVE NEUROMODULATION DEVICES MARKET REVENUE, BASED ON PRODUCT TYPE, (2021-2029) ($MN)
      • TABLE 72     APAC NON-INVASIVE NEUROMODULATION DEVICES MARKET REVENUE, BASED ON PRODUCT TYPE, (2021-2029) ($MN)
      • TABLE 73     APAC NEUROMODULATION DEVICES MARKET REVENUE, BASED ON APPLICATION, (2021-2029) ($MN)
      • TABLE 74     APAC PAIN MANAGEMENT MARKET REVENUE, BASED ON APPLICATION TYPE, (2021-2029) ($MN)
      • TABLE 75     APAC CENTRAL NERVOUS SYSTEM MARKET REVENUE, BASED ON APPLICATION TYPE, (2021-2029) ($MN)
      • TABLE 76     APAC GASTROENTEROLOGY AND UROLOGY MARKET REVENUE, BASED ON APPLICATION TYPE, (2021-2029) ($MN)
      • TABLE 77     APAC NEUROMODULATION DEVICES MARKET REVENUE, BASED ON END-USERS, (2021-2029) ($MN)
      • TABLE 78     APAC NEUROMODULATION DEVICES MARKET REVENUE, BASED ON COUNTRY, (2021-2029) ($MN)
      • TABLE 79     JAPAN NEUROMODULATION DEVICES GLOBAL MARKET REVENUE, BASED ON PRODUCTS (2022) ($ MN)
      • TABLE 80     CHINA NEUROMODULATION DEVICES GLOBAL MARKET REVENUE, BASED ON PRODUCTS (2022) ($ MN)
      • TABLE 81     INDIA NEUROMODULATION DEVICES GLOBAL MARKET REVENUE, BASED ON PRODUCTS (2022) ($ MN)
      • TABLE 82     REST OF APAC NEUROMODULATION DEVICES GLOBAL MARKET REVENUE, BASED ON PRODUCTS (2022) ($ MN)
      • TABLE 83     ROW NEUROMODULATION DEVICES MARKET REVENUE, BASED ON PRODUCT, (2021-2029) ($MN)
      • TABLE 84     ROW INVASIVE NEUROMODULATION DEVICES MARKET REVENUE, BASED ON PRODUCT TYPE, (2021-2029) ($MN)
      • TABLE 85     ROW NON-INVASIVE NEUROMODULATION DEVICES MARKET REVENUE, BASED ON PRODUCT TYPE, (2021-2029) ($MN)
      • TABLE 86     ROW NEUROMODULATION MARKET REVENUE, BASED ON APPLICATION, (2021-2029) ($MN)
      • TABLE 87     ROW PAIN MANAGEMENT MARKET REVENUE, BASED ON APPLICATION TYPE, (2021-2029) ($MN)
      • TABLE 88     ROW CENTRAL NERVOUS SYSTEM MARKET REVENUE, BASED ON APPLICATION TYPE, (2021-2029) ($MN)
      • TABLE 89     ROW GASTROENTEROLOGY AND UROLOGY MARKETREVENUE, BASED ON APPLICATION TYPE, (2021-2029) ($MN)
      • TABLE 90     ROW NEUROMODULATION DEVICES MARKET REVENUE, BASED ON END-USERS, (2021-2029) ($MN)
      • TABLE 91     ROW NEUROMODULATION DEVICES MARKET REVENUE, BASED ON COUNTRY, (2021-2029) ($MN)
      • TABLE 92     BRAZIL NEUROMODULATION DEVICES GLOBAL MARKET REVENUE, BASED ON PRODUCTS (2022) ($ MN)
      • TABLE 93     REST OF LATAM NEUROMODULATION DEVICES GLOBAL MARKET REVENUE, BASED ON PRODUCTS (2022) ($ MN)
      • TABLE 94     MIDDLE EAST AND OTHERS NEUROMODULATION DEVICES GLOBAL MARKET REVENUE, BASED ON PRODUCTS (2022) ($ MN)
      • TABLE 95     PRODUCT APPROVAL (2020-2022)
      • TABLE 96     PRODUCT LAUNCH (2020-2022)
      • TABLE 97     EXPANSION AND ACQUISITION (2020-2022)
      • TABLE 98     AGREEMENT AND COLLABORATION (2020-2022)
      • TABLE 99     OTHER DVELOPMENTS (2020-2022)
      • TABLE 100     ABBOTT LABORATORIES.: TOTAL REVENUE AND R&D EXPENSES, (2019-2021) ($MN)
      • TABLE 101     ABBOTT LABORATORIES.: TOTAL REVENUE, BASED ON SEGMENT, (2019-2021) ($MN)
      • TABLE 102     ABBOTT LABORATORIES.: TOTAL REVENUE, BASED ON SUB-SEGMENT, (2019-2021) ($MN)
      • TABLE 103     ABBOTT LABORATORIES.: TOTAL REVENUE, BASED ON GEOGRAPHY, (2019-2021) ($MN)
      • TABLE 104     AXONICS INC.: TOTAL REVENUE AND R&D EXPENSES (2020-2022 (Q1)) ($MN)
      • TABLE 105     AXONICS INC.: TOTAL REVENUE, BASED ON SEGMENT, (2020-2022 (Q1)) ($MN)
      • TABLE 106     AXONICS INC.: TOTAL REVENUE, BASED ON REGION, (2020-2022 (Q1)) ($MN)
      • TABLE 107     BIOVENTUS.: TOTAL REVENUE AND R&D EXPENSES (2020-2022 (Q1)) ($MN)
      • TABLE 108     BIOVENTUS.: TOTAL REVENUE, BASED ON SEGMENT, (2020-2022 (Q1)) ($MN)
      • TABLE 109     BIOVENTUS.: TOTAL REVENUE, BASED ON REGION, (2020-2022 (Q1)) ($MN)
      • TABLE 110     BOSTON SCIENTIFIC CORPORATION : TOTAL REVENUE AND R&D EXPENSES, (2020-2022 (Q1)) ($MN)
      • TABLE 111     BOSTON SCIENTIFIC CORPORATION: TOTAL REVENUE, BASED ON SEGMENT, (2020-2022 (Q1)) ($MN)
      • TABLE 112     BOSTON SCIENTIFIC CORPORATION: TOTAL REVENUE, BASED ON GEOGRAPHY, (2020-202 (Q1)) ($MN)
      • TABLE 113     INSPIRE MEDICAL SYSTEM, INC.: TOTAL REVENUE AND R&D EXPENSES, (2020-2022 (Q1)) ($MN)
      • TABLE 114     INSPIRE MEDICAL SYSTEM,INC.: TOTAL REVENUE, BASED ON GEOGRAPHY, (2020-2022 (Q1)) ($MN)
      • TABLE 115     LIVANOVA PLC.: TOTAL REVENUE AND R&D EXPENSES, (2020-2022 (Q1)) ($MN)
      • TABLE 116     LIVANOVA PLC.: TOTAL REVENUE, BASED ON SEGMENT, (2020-2022 (Q1)) ($MN)
      • TABLE 117     LIVANOVA PLC.: TOTAL REVENUE, BASED ON GEOGRAPHY, (2020-2022 (Q1)) ($MN)
      • TABLE 118     MEDTRONIC, PLC.: TOTAL REVENUE AND R&D EXPENSES, (2020-2022 (Q3)) ($MN)
      • TABLE 119     MEDTRONIC, PLC.: TOTAL REVENUE, BASED ON SEGMENT, (2020-2022 (Q3)) ($MN)
      • TABLE 120     MEDTRONIC, PLC.: TOTAL REVENUE, BASED ON SUB-SEGMENT (NEUROSCIENCE)(2020-2022 (Q3)) ($MN)
      • TABLE 121     MEDTRONIC, PLC.: TOTAL REVENUE, BASED ON GEOGRAPHY, (2020-2022 (Q3)) ($MN)
      • TABLE 122     NEUROPACE, INC.: TOTAL REVENUE AND R&D EXPENSES, (2020-2022 (Q1)) ($MN)
      • TABLE 123     NEVRO CORPORATION : TOTAL REVENUE AND R&D EXPENSES (2020-2022 (Q1)) ($MN)
      • TABLE 124     NEVRO CORPORATION: TOTAL REVENUE, BASED ON GEOGRAPHY, (2020-2022 (Q1)) ($MN)

      LIST OF FIGURES

      • FIGURE 1     NEUROMODULATION DEVICES GLOBAL MARKET REVENUE, BASED ON REGION (2021-2029) ($MN)
      • FIGURE 2     RESEARCH METHODOLOGY: NEUROMODULATION DEVICES GLOBAL MARKET
      • FIGURE 3     NEUROMODULATION DEVICES GLOBAL MARKET: TOP-DOWN AND BOTTOM-UP APPROACH
      • FIGURE 4     NEUROMODULATION DEVICES GLOBAL MARKET: FORECASTING MODEL
      • FIGURE 5     NEUROMODULATION DEVICES GLOBAL MARKET: MARKET BREAKDOWN AND DATA TRIANGULATION
      • FIGURE 6     NEUROMODULATION DEVICES GLOBAL MARKET SEGMENTATION
      • FIGURE 7     MARKET DYNAMICS
      • FIGURE 8     NEUROMODULATION DEVICES CLINICAL TRIAL ANALYSIS
      • FIGURE 9     NEUROMODULATION DEVICES GLOBAL MARKET: PORTER’S ANALYSIS
      • FIGURE 10     NEUROMODULATION DEVICES: SUPPLY CHAIN ANALYSIS
      • FIGURE 11     NEUROMODULATION DEVICES GLOBAL MARKET SHARE ANALYSIS, BASED ON KEY PLAYERS, 2022 (%)
      • FIGURE 12     SPINAL CORD STIMULATOR (SCS) GLOBAL MARKET SHARE ANALYSIS, BASED ON KEY PLAYERS, 2022 (%)
      • FIGURE 13     DEEP BRAIN STIMULATOR (DBS) GLOBAL MARKET SHARE ANALYSIS, BASED ON KEY PLAYERS, 2022 (%)
      • FIGURE 14     SACRAL NERVE STIMULATOR (SNS) GLOBAL MARKET SHARE ANALYSIS, BASED ON KEY PLAYERS, 2022 (%)
      • FIGURE 15     HYPOGLOSSAL NERVE STIMULATOR (HGNS) GLOBAL MARKET SHARE ANALYSIS, BASED ON KEY PLAYERS, 2022 (%)
      • FIGURE 16     UNITED STATES OBSTRUCTIVE SLEEP APNEA NEUROMODULATION DEVICES MARKET PENETRATION, 2022 (%)
      • FIGURE 17     UNITED STATES DRUG RESISTANT EPILEPSY NEUROMODULATION DEVICES MARKET PENETRATION, 2022 (%)
      • FIGURE 18     UNITED STATES DEPRESSION NEUROMODULATION DEVICES MARKET PENETRATION, 2022 (%)
      • FIGURE 19     UNITED STATES OVERACTIVE BLADDER NEUROMODULATION DEVICES MARKET PENETRATION, 2022 (%)
      • FIGURE 20     UNITED STATES CHRONIC PAIN NEUROMODULATION DEVICES MARKET PENETRATION, 2022 (%)
      • FIGURE 21     NEUROMODULATION DEVICES GLOBAL MARKET SHARE, BASED ON PRODUCT (2022 V/S 2029) (%)
      • FIGURE 22     INVASIVE NEUROMODULATION DEVICES GLOBAL MARKET SHARE, BASED ON PRODUCT TYPE (2022 V/S 2029) (%)
      • FIGURE 23     SPINAL CORD STIMULATION (SCS) GLOBAL MARKET REVENUE, BASED ON COUNTRY (2022) ($ MN)
      • FIGURE 24     DEEP BRAIN STIMULATION (DBS) GLOBAL MARKET REVENUE, BASED ON COUNTRY (2022) ($ MN)
      • FIGURE 25     SACRAL NERVE STIMULATION (SNS) GLOBAL MARKET REVENUE, BASED ON COUNTRY (2022) ($ MN)
      • FIGURE 26     VAGUS NERVE STIMULATION (VNS) GLOBAL MARKET REVENUE, BASED ON COUNTRY (2022) ($ MN)
      • FIGURE 27     HYPOGLOSSAL NERVE STIMULATION (HGNS) GLOBAL MARKET REVENUE, BASED ON COUNTRY (2022) ($ MN)
      • FIGURE 28     OTHER INVASIVE NEUROMODULATION GLOBAL MARKET REVENUE, BASED ON COUNTRY (2022) ($ MN)
      • FIGURE 29     NON-INVASIVE NEUROMODULATION DEVICES GLOBAL MARKET SHARE, BASED ON PRODUCT TYPE, (2022 V/S 2029) (%)
      • FIGURE 30     TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION (TENS) GLOBAL MARKET REVENUE, BASED ON COUNTRY (2022) ($ MN)
      • FIGURE 31     NEUROMUSCULAR ELECTRICAL STIMULATION (NMES) GLOBAL MARKET REVENUE, BASED ON COUNTRY (2022) ($ MN)
      • FIGURE 32     OTHER NON-INVASIVE NEUROMODULATION DEVICES GLOBAL MARKET REVENUE, BASED ON COUNTRY (2022) ($ MN)
      • FIGURE 33     NEUROMODULATION DEVICES GLOBAL MARKET SHARE, BASED ON APPLICATION (2022 V/S 2029) (%)
      • FIGURE 34     PAIN MANAGEMENT GLOBAL MARKET SHARE, BASED ON APPLICATION TYPE (2022 V/S 2029) (%)
      • FIGURE 35     CENTRAL NERVOUS SYSTEM (CNS) GLOBAL MARKET SHARE, BASED ON APPLICATION TYPE, (2022 V/S 2029) (%)
      • FIGURE 36     GASTROENTEROLOGY AND UROLOGY GLOBAL MARKET SHARE, BASED ON APPLICATION TYPE, (2022 V/S 2029) (%)
      • FIGURE 37     NEUROMODULATION DEVICES GLOBAL MARKET SHARE, BASED ON END-USERS (2022 V/S 2029) (%)
      • FIGURE 38     HOSPITALS AND AMBULATORY SURGERY CENTERS (ASC) GLOBAL MARKET SHARE, BASED ON END-USERS, (2022 V/S 2029) (%)
      • FIGURE 39     CLINICS AND PHYSIOTHERAPY CENTERS GLOBAL MARKET SHARE, BASED ON END-USERS, (2022 V/S 2029) (%)
      • FIGURE 40     OTHERS GLOBAL MARKET SHARE, BASED ON END-USERS, (2022 V/S 2029) (%)
      • FIGURE 41     NEUROMODULATION DEVICES GLOBAL MARKET REVENUE, BASED ON REGION (2021-2029) ($MN), CAGR (%)
      • FIGURE 42     NEUROMODULATION DEVICES GLOBAL MARKET SHARE, BASED ON GEOGRAPHY (2022) (%)
      • FIGURE 43     NORTH AMERICA NEUROMODULATION DEVICES MARKET SHARE, BASED ON PRODUCTS, (2022 V/S 2029) (%)
      • FIGURE 44     NORTH AMERICA INVASIVE NEUROMODULATION DEVICES MARKET SHARE, BASED ON PRODUCT TYPE (2022 V/S 2029) (%)
      • FIGURE 45     NORTH AMERICA NON-INVASIVE NEUROMODULATION DEVICES MARKET SHARE, BASED ON PRODUCT TYPE (2022 V/S 2029) (%)
      • FIGURE 46     NORTH AMERICA NEUROMODULATION DEVICES MARKET SHARE, BASED ON APPLICATION (2022 V/S 2029) (%)
      • FIGURE 47     NORTH AMERICA PAIN MANAGEMENT MARKET SHARE, BASED ON APPLICATION TYPE (2022 V/S 2029) (%)
      • FIGURE 48     NORTH AMERICA CENTRAL NERVOUS SYSTEM MARKET SHARE, BASED ON APPLICATION TYPE (2022 V/S 2029) (%)
      • FIGURE 49     NORTH AMERICA GASTROENTEROLOGY/UROLOGY MARKET SHARE, BASED ON APPLICATION TYPE (2022 V/S 2029) (%)
      • FIGURE 50     NORTH AMERICA NEUROMODULATION DEVICES MARKET SHARE, BASED ON END USER (2022 V/S 2029) (%)
      • FIGURE 51     NORTH AMERICA NEUROMODULATION DEVICES MARKET, BASED ON COUNTRY (2022 V/S 2029) (%)
      • FIGURE 52     U.S. NEUROMODULATION DEVICES MARKET REVENUE, BASED ON PRODUCTS AND APPLICATIONS (2022 V/S 2029) ($MN)
      • FIGURE 53     U.S. NEUROMODULATION DEVICES MARKET REVENUE, BASED ON END USERS (2022 V/S 2029) ($MN)
      • FIGURE 54     REST OF NORTH AMERICA NEUROMODULATION DEVICES MARKET REVENUE, BASED ON PRODUCTS AND APPLICATIONS (2022 V/S 2029) ($MN)
      • FIGURE 55     REST OF NORTH AMERICA NEUROMODULATION DEVICES MARKET REVENUE, BASED ON END USERS (2022 V/S 2029) ($MN)
      • FIGURE 56     EUROPE NEUROMODULATION DEVICES MARKET SHARE, BASED ON PRODUCT, (2022 V/S 2029) (%)
      • FIGURE 57     EUROPE INVASIVE NEUROMODULATION DEVICES MARKET SHARE, BASED ON PRODUCT TYPE (2022 V/S 2029) (%)
      • FIGURE 58     EUROPE NON-INVASIVE NEUROMODULATION DEVICES MARKET SHARE, BASED ON PRODUCT TYPE (2022 V/S 2029) (%)
      • FIGURE 59     EUROPE NEUROMODULATION DEVICES MARKET SHARE, BASED ON APPLICATION (2022 V/S 2029)
      • FIGURE 60     EUROPE PAIN MANAGEMENT MARKET REVENUE, BASED ON APPLICATION TYPE (2022 V/S 2029) (%)
      • FIGURE 61     EUROPE CENTRAL NERVOUS SYSTEM MARKET SHARE, BASED ON APPLICATION TYPE (2022 V/S 2029) (%)
      • FIGURE 62     EUROPE GASTROENTEROLOGY/UROLOGY MARKET SHARE, BASED ON APPLICATION TYPE (2022 V/S 2029) (%)
      • FIGURE 63     EUROPE NEUROMODULATION DEVICES MARKET SHARE, BASED ON END USERS (2022 V/S 2029) (%)
      • FIGURE 64     EUROPE NEUROMODULATION DEVICES MARKET SHARE, BASED ON COUNTRY (2022 V/S 2029) (%)
      • FIGURE 65     GERMANY NEUROMODULATION DEVICES MARKET REVENUE, BASED ON PRODUCTS AND APPLICATIONS (2022 V/S 2029) ($MN)
      • FIGURE 66     GERMANY NEUROMODULATION DEVICES MARKET REVENUE, BASED ON END-USERS (2022 V/S 2029) ($MN)
      • FIGURE 67     FRANCE NEUROMODULATION DEVICES MARKET REVENUE, BASED ON PRODUCTS AND APPLICATIONS (2022 V/S 2029) ($MN)
      • FIGURE 68     FRANCE NEUROMODULATION DEVICES MARKET REVENUE, BASED ON END USERS (2022 V/S 2029) ($MN)
      • FIGURE 69     U.K. NEUROMODULATION DEVICES MARKET REVENUE, BASED ON PRODUCTS AND APPLICATIONS (2022 V/S 2029) ($MN)
      • FIGURE 70     U.K. NEUROMODULATION DEVICES MARKET REVENUE, BASED ON END USERS (2022 V/S 2029) ($MN)
      • FIGURE 71     REST OF EUROPE NEUROMODULATION DEVICES MARKET REVENUE, BASED ON PRODUCT AND APPLICATION (2022 V/S 2029) ($MN)
      • FIGURE 72     REST OF EUROPE NEUROMODULATION DEVICES MARKET REVENUE, BASED ON END USER (2022 V/S 2029) (%)
      • FIGURE 73     APAC NEUROMODULATION DEVICES MARKET SHARE, BASED ON PRODUCT, (2022 V/S 2029) (%)
      • FIGURE 74     APAC INVASIVE NEUROMODULATION DEVICES MARKET SHARE, BASED ON PRODUCT TYPE (2022 V/S 2029) (%)
      • FIGURE 75     APAC NON-INVASIVE NEUROMODULATION DEVICES MARKET SHARE, BASED ON PRODUCT TYPE (2022 V/S 2029) (%)
      • FIGURE 76     APAC NEUROMODULATION DEVICES MARKET SHARE, BASED ON APPLICATION (2022 V/S 2029) (%)
      • FIGURE 77     APAC PAIN MANAGEMENT MARKET SHARE, BASED ON APPLICATION TYPE (2022 V/S 2029) (%)
      • FIGURE 78     APAC CENTRAL NERVOUS SYSTEM MARKET SHARE, BASED ON APPLICATION TYPE (2022 V/S 2029) (%)
      • FIGURE 79     APAC GASTROENTEROLOGY/UROLOGY MARKET SHARE, BASED ON APPLICATION TYPE (2022 V/S 2029) (%)
      • FIGURE 80     APAC GASTROENTEROLOGY/UROLOGY MARKET SHARE, BASED ON END USERS (2022 V/S 2029) (%)
      • FIGURE 81     APAC NEUROMODULATION DEVICES MARKET SHARE, BASED ON COUNTRY (2022 V/S 2029) (%)
      • FIGURE 82     JAPAN NEUROMODULATION DEVICES MARKET REVENUE, BASED ON PRODUCT AND APPLICATION (2022 V/S 2029) ($MN)
      • FIGURE 83     JAPAN NEUROMODULATION DEVICES MARKET REVENUE, BASED ON END USER (2022 V/S 2029) ($MN)
      • FIGURE 84     CHINA NEUROMODULATION DEVICES MARKET REVENUE, BASED ON PRODUCTS AND APPLICATIONS (2022 V/S 2029) ($MN)
      • FIGURE 85     CHINA NEUROMODULATION DEVICES MARKET REVENUE, BASED ON END USERS (2022 V/S 2029) ($MN)
      • FIGURE 86     INDIA NEUROMODULATION DEVICES MARKET REVENUE, BASED ON PRODUCTS AND APPLICATIONS (2022 V/S 2029) ($MN)
      • FIGURE 87     INDIA NEUROMODULATION DEVICES MARKET REVENUE, BASED ON END USERS (2022 V/S 2029) ($MN)
      • FIGURE 88     REST OF APAC NEUROMODULATION DEVICES MARKET REVENUE, BASED ON PRODUCT AND APPLICATION (2022 V/S 2029) ($MN)
      • FIGURE 89     REST OF APAC NEUROMODULATION DEVICES MARKET REVENUE, BASED ON END USER (2022 V/S 2029) ($MN)
      • FIGURE 90     ROW NEUROMODULATION DEVICES MARKET SHARE, BASED ON PRODUCT (2022 V/S 2029) (%)
      • FIGURE 91     ROW INVASIVE NEUROMODULATION DEVICES MARKET SHARE, BASED ON PRODUCT TYPE (2022 V/S 2029) (%)
      • FIGURE 92     ROW NON-INVASIVE NEUROMODULATION DEVICES MARKET SHARE, BASED ON PRODUCT TYPE (2022 V/S 2029) (%)
      • FIGURE 93     ROW NEUROMODULATION DEVICES MARKET SHARE, BASED ON APPLICATION (2022 V/S 2029) (%)
      • FIGURE 94     ROW PAIN MANAGEMENT MARKET SHARE, BASED ON APPLICATION TYPE (2022 V/S 2029) (%)
      • FIGURE 95     ROW CENTRAL NERVOUS SYSTEM MARKET SHARE, BASED ON APPLICATION TYPE (2022 V/S 2029) (%)
      • FIGURE 96     ROW GASTROENTEROLOGY/UROLOGY MARKET SHARE, BASED ON APPLICATION TYPE (2022 V/S 2029) (%)
      • FIGURE 97     ROW NEUROMODULATION DEVICES MARKET SHARE, BASED ON END USER (2022 V/S 2029) (%)
      • FIGURE 98     ROW NEUROMODULATION DEVICES MARKET SHARE, BASED ON COUNTRY (2022 V/S 2029) (%)
      • FIGURE 99     BRAZIL NEUROMODULATION DEVICES MARKET REVENUE, BASED ON PRODUCTS AND APPLICATIONS (2022 V/S 2029) ($MN)
      • FIGURE 100     BRAZIL NEUROMODULATION DEVICES MARKET REVENUE, BASED ON END USERS (2022 V/S 2029) ($MN)
      • FIGURE 101     REST OF LATAM NEUROMODULATION DEVICES MARKET REVENUE, BASED ON PRODUCT AND APPLICATION (2022 V/S 2029) ($MN)
      • FIGURE 102     REST OF LATAM NEUROMODULATION DEVICES MARKET REVENUE, BASED ON END USER (2022 V/S 2029) ($MN)
      • FIGURE 103     MIDDLE EAST AND OTHERS NEUROMODULATION DEVICES MARKET REVENUE, BASED ON PRODUCT AND APPLICATION (2022 V/S 2029) ($MN)
      • FIGURE 104     MIDDLE EAST AND OTHERS NEUROMODULATION DEVICES MARKET REVENUE, BASED ON END USER (2022 V/S 2029) ($MN)
      • FIGURE 105     KEY GROWTH STRATEGIES, (2020-2022)
      • FIGURE 106     SWOT: ABBOTT LABORATORIES
      • FIGURE 107     SWOT: AXONICS INC.
      • FIGURE 108     SWOT: BIOVENTUS
      • FIGURE 109     SWOT: BOSTON SCIENTIFIC CORPORATION
      • FIGURE 110     SWOT: INSPIRE MEDICAL SYSTEM, INC.
      • FIGURE 111     SWOT: LABORIE MEDICAL TECHNOLOGY INC.
      • FIGURE 112     SWOT: LIVANOVA PLC
      • FIGURE 113     SWOT: MEDTRONIC PLC.
      • FIGURE 114     SWOT: NEUROPACE, INC.
      • FIGURE 115     SWOT: NEVRO CORPORATION

      LIST OF COMPANIES MENTIONED IN THE REPORT

      • 1     Abbott Laboratories
      • 2     Algostim
      • 3     Ates Medica Device Srl
      • 4     Atrotech Oy
      • 5     Attune Neurosciences
      • 6     Auri- Stim Medical, Inc  
      • 7     Avery Biomedical Devices Inc.
      • 8     Axilum Robotics
      • 9     AxioBionics LLC
      • 10     Axonics Inc.
      • 11     Baldoni Neuromodulation
      • 12     Beijing Pins Medical Co., Ltd.
      • 13     Biocontrol Medical
      • 14     Bioinduction Ltd.
      • 15     Bioness Inc.
      • 16     Bioventus Inc. (Bioness Inc.,)
      • 17     BioWave
      • 18     BlueWind Medical
      • 19     Boston Scientific Corporation
      • 20     Bottneuro
      • 21     Brainsway Ltd.
      • 22     Cafely
      • 23     Cala Health
      • 24     Cardia Care
      • 25     Cochlear Ltd
      • 26     Comphya
      • 27     Cortec GmbH
      • 28     Corveus Medical
      • 29     CVRx
      • 30     Cyberonics, Inc.
      • 31     Cymedica Orthopedics
      • 32     Desyncra Technologies
      • 33     Djo Global (Colfax Corp.)
      • 34     Dw Healthcare (Cefaly Technology)
      • 35     DyAnsys
      • 36     EB Neuro S.P.A.
      • 37     electroCore
      • 38     eNeura Inc.
      • 39     Epineuron Technologies, Inc.
      • 40     Gimer Medical
      • 41     Greatbatch Medical
      • 42     G-Therapeutics
      • 43     Helius Medical Technologies
      • 44     Heuro Canada
      • 45     InnoCon Medical
      • 46     Innovative Health Solutions.
      • 47     Insai
      • 48     Inspire Medical Systems
      • 49     IntraPace
      • 50     JumpStart Inc
      • 51     Laborie Medical Technologies Inc. (Cogentix Medical)
      • 52     Livanova Plc (Sorin Group)
      • 53     Magnus Medical
      • 54     Magstim TMS
      • 55     Magventure A/S
      • 56     Mainstay Medical
      • 57     Medtronic Plc
      • 58     MetaCure, Ltd
      • 59     MicroTransponder Inc.
      • 60     Nalu Medical
      • 61     NDI Medical
      • 62     NeoSync
      • 63     Nesos
      • 64     Neuralace Medical
      • 65     NeurAxis
      • 66     Neurocare Group GMBH
      • 67     Neuroelectrics
      • 68     NeuroEm Therapeutics Inc.
      • 69     Neurolief Ltd.
      • 70     NeuroMetrix
      • 71     Neuronetics
      • 72     Neuropace Inc.
      • 73     Neuros Medical, Inc.
      • 74     Neurosigma Inc
      • 75     Neurovalens
      • 76     Nevro Corporation
      • 77     Nexstim Plc
      • 78     Northstar Neuroscience
      • 79     Nuraleve Inc
      • 80     Nuvectra Corporation
      • 81     Nyxoah SA
      • 82     ODstock Medical
      • 83     Olympic Ophthamalic Inc.
      • 84     Onward Medical
      • 85     Pathmaker Neurosystems Inc.
      • 86     Phagenesis
      • 87     Precidio Medical
      • 88     Precisis AG
      • 89     Pulvinar Neuro (Electromedical Products International, Inc,(EPI))
      • 90     REMED Co., Ltd.
      • 91     Rogue research
      • 92     Saluda Medical
      • 93     Salvia Bioelectronics
      • 94     Sana Health
      • 95     SceneRay Technologies
      • 96     Set Point Medical
      • 97     ShiraTronics
      • 98     Signifier Medical Technologies Ltd
      • 99     Sooma Oy
      • 100     Soterix Medical
      • 101     Spark Biomedical
      • 102     SPR Therapeutics
      • 103     Stimdia Medical Inc,
      • 104     Stimwave LLC
      • 105     Sublimed
      • 106     Synapse Biomedical Inc.
      • 107     Syneika
      • 108     Theranica Bio-Electronics Ltd.
      • 109     tVNS Technologies
      • 110     Uroplasty, Inc.
      • 111     Vertis Neurosciences
      • 112     Ybrain, INC
      • 113     ZOLL Medical Corporation (Respicardia, Inc.)
      • 114     Zosano
      • 115     Zynex Medical, Inc.